Roche will present new data on rheumatoid arthritis (RA) and severe inflammatory disorders at the 16th European League Against Rheumatism Annual Congress (EULAR 2015) to be held in Rome, 10-13 June, 2015. According to the company’s press release, this will include 40 data presentations across 7 autoimmune conditions as well as new results from RoACTEMRA in early RA and systemic sclerosis (SSc), a potentially fatal disease with limited treatment options. In 2014, Roche’s RoACTEMRA (tocilizumab) received approval from the European Commission for use in patients with early, severe, active and progressive RA who have previously not been treated with methotrexate (MTX).
Rheumatoid arthritis is an autoimmune disease and affects over 21 million people worldwide. Characterized by chronic inflammation (mainly of the joints), pain and fatigue, RA can have a detrimental impact on quality of life. As a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics, Roche is well known for its efforts to change the treatment for RA. With positive results from a large number of international clinical trials, Roche believes that it can help patients with RA achieve remission – the stage when all or most of the symptoms of the disease have disappeared and there is no longer any progressive damage to the joints.
The European League Against Rheumatism (EULAR) is the organization that represents the patient, health professional and scientific societies of rheumatology of all the European nations. It aims at reducing the burden of rheumatic diseases on the individual and society and improves the treatment, prevention and rehabilitation of musculoskeletal diseases. The first EULAR conference was held in 1947 and since 2000 it has become an annual tradition and has grown to become a major international event in the rheumatology calendar.
Roche’s data at EULAR 2015 will include presentations and posters demonstrating the company’s involvement in developing effective treatment for RA and other autoimmune diseases. The titles of its presentations are:
- Rapid and sustained remission in early rheumatoid arthritis treated to target with tocilizumab, methotrexate, or their combination: the U-ACT-EARLY strategy study
- Safety and efficacy of subcutaneous (SC) tocilizumab (TCZ) in adults with systemic sclerosis (SSc): week 48 data from the FaSScinate trial
With the discovery of innovative new therapies which target the root causes of joint inflammation, Roche is helping change the way that RA is treated and making a positive difference in the well-being and quality of life of patients.
Sandra Horning, M.D., Roche’s Head of Global Product Development and Chief Medical Officer says, “People with rheumatological conditions have relied on our medicines for more than a decade, and we are committed to developing treatments for other debilitating autoimmune diseases. We are proud to apply our insights into the biology of inflammation to conditions where patients have inadequate, or no currently approved, treatment options.”